Annovis Bio adds to leadership team

Malvern-based Annovis Bio, a late-stage clinical drug platform company specializing in neurodegeneration diseases, recently added four members to its executive team.

“We are delighted to have this strong group of individuals join the Annovis team,” said Maria Maccecchini, Ph.D., Annovis Bio founder, president, and CEO. “Their expertise and leadership are critical in this pivotal moment in our company, as we continue making strides towards bringing buntanetap closer to NDA (new drug application) and to market for Alzheimer’s and Parkinson’s diseases.”

Mark White was appointed chief business officer. White is a member of the Annovis Bio board of directors. He has experience in business development, global pharmaceutical marketing, and sales.

Dr. Alexander Morin was appointed director of strategic communications. Morin has experience working with science and communications in the biopharmaceutical industry. He comes to Annovis Bio from a boutique public relations firm where he was a account executive.

Hilda Maibach was appointed senior vice president of statistics. Maibach has more than 30 years of experience with clinical and observational studies addressing central nervous system disorders, infectious disease, metabolic disorders and oncology. She also has experience with the Centers for Disease Control.

Blake Jensen was appointed head of quality. Jensen has more than 20 years quality control experience with contract service providers and biopharma companies. He also previously worked as an investigator for the U.S. Food and Drug Administration.

The post Annovis Bio adds to leadership team appeared first on Pennsylvania Business Report .